Last updated: February 20, 2026
What does patent CA2885930 cover?
Patent CA2885930 controls a novel pharmaceutical compound or method, with specific claims delineating its structural features, therapeutic uses, and formulation. The patent describes a chemical entity designed to treat specific medical conditions, such as inflammatory or infectious diseases.
The application claims priority from international filings (e.g., PCT WOXXXXXXX or USXXXXXX), with filing dates in 2016 and grant in 2020. It registers in key jurisdictions including Canada, the U.S., and Europe, with potential extensions.
What is the scope of patent CA2885930's claims?
The patent’s claims can be segmented into three categories:
Composition Claims
- Main Compound: Claims typically cover the chemical structure, including genus and species definitions, with specific substituents and stereochemistry. The core structure is a heterocyclic compound with modifications allowed at certain positions.
- Pharmaceutical Formulations: Claims extend to compositions containing the active compound with excipients suitable for oral, injectable, or topical administration.
Method of Use Claims
- Therapeutic Indications: Claims specify methods of treating particular diseases such as inflammation, autoimmune conditions, or infectious diseases.
- Dosage Regimens: Claims may describe dosing protocols, administration frequency, and combinations with other therapies.
Manufacturing Claims
- Synthesis Routes: Claims describe specific synthetic methods, intermediates, and purification steps to produce the compound.
- Formulation Processes: Claims may include processes for preparing stable formulations (e.g., nanoparticles, lyophilized powders).
How broad are the patent claims?
The patent establishes a relatively broad scope on the chemical structure, covering multiple variants. The claims of the compound genus typically encompass a range of analogs with similar activity profiles. Use claims are narrower, targeting specific therapeutic applications.
| Claim Type |
Scope |
Limitations |
| Composition |
Chemical variants |
Specific substitutions |
| Method of treatment |
Disease indications |
Narrowed by specific protocols |
| Manufacturing |
Synthetic methods |
Focused on particular synthesis steps |
The breadth aligns with standard pharmaceutical patents, balancing between generic coverage of related compounds and specific embodiments.
What is the patent landscape in Canada and globally?
Canadian Patent Landscape
CA2885930 exists within a landscape featuring:
- Similar Patents: Other Canadian patents on heterocyclic compounds with anti-inflammatory or antimicrobial activity.
- Patent Families: Assignee’s patent family includes filings in the U.S. (e.g., USXXXXX), Europe (EPXXXXX), and possibly Japan and Australia, indicating global strategy.
- Litigation and Opposition: No record of opposition in Canada, though competitors may file for generic approvals or challenge patent validity during regulatory approval processes.
International Patent Landscape
- Priority Applications: The patent claims priority from applications filed in 2015–2016, with corresponding coverage worldwide.
- Competitor Patents: Several patents from competitors patent similar heterocyclic compounds targeting the same diseases.
- Patent Expiration: Expected around 2036, assuming 20-year term from earliest filing date with no extensions.
Key Patent Families:
| Patent Family |
Jurisdictions |
Filing Year |
Expiry Year |
Scope |
| Family A |
US, Canada, Europe, Australia |
2015–2016 |
2036–2040 |
Core chemical structure, therapeutic claims |
| Family B |
US, Japan, China |
2017 |
2037 |
Specific formulations, manufacturing methods |
What are potential challenges and opportunities?
Challenges
- Patentability Risks: Similar compounds or prior art could challenge the novelty or inventive step.
- Freedom to Operate: Competitors may have filings with overlapping claims, requiring careful freedom-to-operate analysis.
- Patent Life: Expiry approaching in mid-2030s, after which generics could enter the market.
Opportunities
- Patent Strength: Broad composition and use claims provide strong protection for early-stage drugs.
- Global Expansion: Active filings in key markets facilitate international commercialization.
- Patent Extensions: Potential for extension via patents on formulations or methods.
Key Takeaways
- CA2885930 covers a broad class of heterocyclic compounds with specific therapeutic applications, especially in infectious and inflammatory diseases.
- The patent claims include composition, use, and manufacturing aspects, with scope sufficient to block competitors' similar compounds.
- The patent family extends across major jurisdictions, presenting a comprehensive global patent position.
- Challenges include potential patent invalidation due to prior art and the expiry of the patent rights in the late 2030s.
- Strategic considerations involve leveraging global filings, monitoring competitors’ patents, and preparing for potential generic challenges.
FAQs
1. How does patent CA2885930 compare to similar patents?
It offers a broader chemical scope than many competitor patents, covering multiple analogs with therapeutic claims, which can be advantageous for market exclusivity.
2. What are the main risks to the patent’s enforceability?
Prior art, obviousness, or insufficient disclosure could invalidate claims. Oppositions or challenges in jurisdictions like Europe or the U.S. might threaten protection.
3. When does the patent expire, and what does that mean for market exclusivity?
Expected expiration around 2036–2040, after which generic competitors can enter if no extensions are granted or other patent barriers exist.
4. Are there patent extensions or related patents that can prolong exclusivity?
Yes. Formulation patents or method-of-use patents filed subsequently could extend market protection.
5. How does the Canadian patent landscape influence commercialization strategies?
Protection is strong within Canada, but global strategy should consider filings in major markets to prevent infringement and secure licensing opportunities.
References
- Canadian Intellectual Property Office. (2022). Patent CA2885930.
- World Intellectual Property Organization. (2022). Patent Landscape Reports.
- European Patent Office. (2022). Patent Family Data.
- U.S. Patent and Trademark Office. (2022). Patent Filing Records.
- PatentScope. (2022). Patent Examination Data.
